• Takeda would like to announce the launch of Prostap® DCS (leuprorelin acetate dual chamber syringe)
• Prostap® DCS offers a more simple, intuitive and efficient delivery system compared to the original Prostap® vial and syringe mechanism.
• Prostap® DCS offers the same active ingredient as Prostap® and provides well-documented, long-term efficacy and survival outcomes in all stages of prostate cancer.

Takeda would like to announce the launch of Prostap® DCS (leuprorelin acetate dual chamber syringe). A new presentation of leuprorelin acetate (Prostap® ), a treatment for prostate cancer in men and endometriosis and uterine fibroids in women, Prostap DCS® will be available in Ireland at no extra cost to the health service and will replace current presentations of Prostap® when stocks are exhausted.

Prostap® DCS is the only LHRH agonist delivered via a Dual Chamber Syringe (DCS), offering a more simple, intuitive and efficient delivery system compared to the original Prostap® vial and syringe mechanism. As a result, Prostap® DCS will allow healthcare professionals to have more patient-facing time.

Ms. Helen Forristal, Clinical Nurse Specialist, St. Vincent’s University Hospital, Dublin, commented, “The availability of Prostap® DCS will offer a positive change to the treatment of prostate cancer. The simple device will save time in clinics while still providing the effectiveness that we see with Prostap® . As a result, patient care will be improved as we will be able to deliver an effective medicine whilst spending more time with our patients, providing them with much needed support and advice.”

Prostap® DCS delivers the same active ingredient contained within Prostap® (leuprorelin acetate) and provides well-documented, long-term efficacy and survival outcomes in all stages of prostate cancer. It will be available in the same dosages as existing presentations: one-month Prostap® SR DCS (leuprorelin acetate depot injection 3.75mg) and three-month Prostap® 3 DCS (leuprorelin acetate depot injection 11.25mg). To ensure patients receive Prostap® DCS as prescribed, it is necessary to reflect this important change of name on prescriptions with immediate effect to ensure patients receive continuous treatment with Prostap® DCS.

Takeda has been involved with the management and treatment of prostate cancer since the discovery and development of leuprorelin acetate (Prostap® ) in the 1970s. As an organisation Takeda is committed to developing treatments such as Prostap® DCS which offer an overall package of care: long-term efficacy and survival outcomes coupled with a simple and efficient delivery system.

Further information on Prostap® DCS is available at www.ProstateCancerUpdate.ie or from Takeda Medical Information contactable on medinfo@takeda.co.uk or +44 1628 537975.

This image is available in original resolution to logged-in users.

Prostap 3 DCS - everything is provided within each pack to support reconstitution and administration (needle shown is not actual size).